{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:56:47Z","timestamp":1780581407843,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":3076,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/jto.0b013e318074bbf5","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T14:35:12Z","timestamp":1209911712000},"page":"645-651","source":"Crossref","is-referenced-by-count":34,"title":["Phase II Trial of Paclitaxel\u2013Topotecan\u2013Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002"],"prefix":"10.1016","volume":"2","author":[{"given":"Antonius A.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Bogart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia D.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio M. S. Rocha","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett E.","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318074bbf5_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib2","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1989.7.9.1333","article-title":"A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer","volume":"7","author":"Slevin","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"Von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1995.13.6.1430","article-title":"Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Group study","volume":"13","author":"Ettinger","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00000421-199910000-00019","article-title":"Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group","volume":"22","author":"Kirschling","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/bjc.1998.54","article-title":"A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer","volume":"77","author":"Smit","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib8","first-page":"527","article-title":"Low-level taxane exposure increases the activity of topoisomerase I targeted agents [abstract]","volume":"39","author":"Madden","year":"1998","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib9","first-page":"1425","article-title":"Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process","volume":"57","author":"Whitacre","year":"1997","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s002800050545","article-title":"The significance of the sequence of administration of topotecan and etoposide","volume":"39","author":"Bonner","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib11","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bjc.1996.243","article-title":"Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor","volume":"73","author":"Schellens","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.1993.11.2.374","article-title":"Bioavailability of low-dose oral etoposide","volume":"11","author":"Hande","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.2001.19.6.1743","article-title":"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer","volume":"19","author":"Von Pawel","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib14","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.20330","article-title":"A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors","volume":"100","author":"Rocha Lima","year":"2004","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib15","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1200\/JCO.1996.14.6.1964","article-title":"Treatment-related fatal sepsis from topotecan\/cisplatin and topotecan\/paclitaxel","volume":"14","author":"Miller","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLC.2002.n.004","article-title":"Novel doublets in extensive-stage small cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430)","volume":"3","author":"Lyss","year":"2002","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijrobp.2003.10.021","article-title":"70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808","volume":"59","author":"Bogart","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib22","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732","volume":"23","author":"Niell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib23","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2005.05.3181","article-title":"Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis","volume":"24","author":"Spiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.2005.02.9793","article-title":"Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer","volume":"24","author":"De Ruysscher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib25","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2006.07.2827","article-title":"Thoracic radiation therapy in limited stage small-cell lung cancer: timing is everything \u2026 Isn't it?","volume":"24","author":"Perry","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318074bbf5_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415311254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415311254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T23:23:21Z","timestamp":1546039401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415311254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1556086415311254"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318074bbf5","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}